Quadrant Biosciences

About Quadrant Biosciences

Quadrant Biosciences, Inc. operates as a life sciences and biotechnology company, focusing on epigenetic diagnostic solutions for significant health issues. The company was incorporated in Delaware on March 13, 2015, initially as Motion Intelligence Inc., and officially changed its name to Quadrant Biosciences Inc. on September 7, 2017. The impetus for its founding came from Richard Uhlig, a former Wall Street executive with a background in biology from Cornell University, after his son sustained a serious concussion in 2014. This personal experience drove him to explore better diagnostic methods for brain injuries, leading to the establishment of the company.

The company is headquartered in Syracuse, New York, on the campus of SUNY Upstate Medical University, and participates in the Start-Up NY program. Quadrant Biosciences has established collaborative research relationships with several academic institutions, including SUNY Upstate Medical University and Penn State College of Medicine, to develop novel biomarker technologies. The business centers on developing non-invasive, saliva-based tests for neurological and developmental disorders by analyzing microRNA (miRNA) and the microbiome. Its revenue is generated through the sale of its diagnostic tests and kits to healthcare providers, clinical laboratories, and other institutions.

A key product is Clarifi ASD™, a saliva-based epigenetic test designed to aid in the diagnosis of autism spectrum disorder (ASD) in children aged 18 months through six years. Launched in December 2019, this prescription-only laboratory-developed test analyzes regulatory RNAs and microbes in saliva to determine the probability of an ASD diagnosis. The goal is to enable earlier diagnosis and intervention for children with autism. In April 2021, the FDA granted Breakthrough Device designation to Clarifi ASD. Beyond autism, Quadrant is developing diagnostic solutions for mild traumatic brain injury (concussion), Parkinson's disease, anorexia, and schizophrenia based on its Clarifi epigenetic diagnostic platform. The company also pivoted its RNA analysis expertise to develop the Clarifi COVID-19 Test Kit in response to the pandemic, receiving Emergency Use Authorization in September 2020.